BIA Regional Breakfast - London
‘AI for drug discovery; revolution or just hype?’
Join us on Thursday 11 April for another popular BIA networking breakfast. This is an ideal opportunity to meet new business contacts, network with members and hear from local members. We will be discussing changes in drug discovery using AI and do the tools offered by AI stand to offer real advances in drug development or have the benefits been exaggerated?
08:30 - 09:30 Registration, networking and breakfast
09:30 – 10:30 Presentation
10:30 – 11:00 Further networking
Latham & Watkins
London, EC2M 3XF
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.
John has a background in cancer research in both academia (Cancer Research UK, University of Glasgow, and University of Cambridge) and pharma (MedImmune). His PhD at the University of Cambridge focused on understanding how tumors become resistant to therapy. He also has experience with multiple start-ups.
Before co-founding GTN, Noor was an assistant professor at Aalborg University in Copenhagen working on machine learning with special interest in generative models. She has more than 50 publications and 1200+ citations. She has co-authored a book on generative methods and has won a number of grants and awards for her research. She served as the Chair of the IEEE Games Technical committee and co-organised task forces and conferences.
Mark Warne, was appointed as Chief Executive Officer of DeepMatter Group plc on the 2 July 2018. Mark, who joined DeepMatter as a Non-Executive Director in September 2015 also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and International life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/2017 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a non-executive director on the boards of hVIVO plc and Ixico plc.
Mark spent 7 years working in Japan at the Protein Engineering Research institute in Osaka, Yamanouchi Pharmaceutical Co. Ltd. (now Astellas) and Helix Research Institute . On returning to the UK he worked at Inpharmatica Ltd a biotechnology company focusing on knowledge-based drug discovery founded by Dame Prof Janet Thornton FRS.
Free for members and non-members